Cytokinetics, Inc.

Pfizer Corporation

Amgen Inc.

Astellas Pharma Gmbh

Smithkline Beecham Corporation

Other

University of California

Global Blood Therapeutics, Inc.

Pfizer Products Inc.

Bradley Paul Morgan

Pu-Ping Lu

David John Morgans, Jr

Alex R Muci

Xiangping Qian

Luke W Ashcraft

Chihyuan Chuang

Erica Anne Kraynack

Scott E Collibee

Gustave Bergnes

Jeffrey Warrington

Todd Tochimoto

Zhe Yang

Antonio Romero

Fady Malik

Hong X Jiang

Bing Yao

Chihyuan (Grace) Chuang

Jianchao Wang

Steven David Knight

Dashyant Dhanak

Jeffrey T Finer

Kevin J Duffy

Nicholas D Adams

Cynthia A Parrish

Andrew Gordon Swick

Wenyue Wang

Mark Vanderwal

Duke Fitch

Rosanna Tedesco

Alexander Ramon Muci

Jeff Gardina

Han-Jie Zhou

Andrew I McDonald

Susumu Yamaki

Kevin K Liu

Jennifer Kuo Chen Huang

Aroop Chandra

Marc Andrew Garard

Hiroaki Tanaka

Robert L Dow

Takashi Kamikubo

Michael G Johnson

Russell Graceffa

Alan C Cheng

Felix Gonzalez Lopez De Turiso

Masanori Miura

Alessandro Boezio

Mikkel V Debenedetto

Tomoyuki Saito

David Joseph St Jean, Jr

Richard Vargas

David C Moebius

Joshua Payette

Ippei Sato

John R Butler

Yuji Matsushima

Yasuhiro Shiina

Justin Malinowski

Kayoko Mihara

Hanmo Zhang

Hiroshi Kiyohara

Munemichi Ohe

Vincent DiMassa

John Yeoman

Sheng Cui

Henry Morrison

Alan James Russell

Kevin Lau

Qing (Kevin) Lu

Alan Martin Allgeier

Matthew Lynn Peterson

Whitney Walter Smith

Kathleen Ann Elias

Karthik Nagapudi

Matthew Pfeiffer

Steven Mennen

Peter Cornelius

Charles Bernard

Adam Lewis Tomasi

Denise Andersen

Karl Bennett Hansen

Neil Fred Langille

Shawn D Walker

Brian Walter Metcalf

Brian M Stoltz

Ralph P Robinson

George Yiannikouros

Sebastien Caille

Ron C Kelly

Kazuyuki Tsuchiya

Jennifer A Lafontaine

Michael Paul Cruskie, Jr

Kyle Quasdorf

Ikumi Kuriwaki

Bin Peter Quan

Takuya Makino

Toshio Kurosaki

Christopher Goss

Eriko Honjo

Provided are compounds of Formula (I): or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R, R, R, and Rare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of using a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

Cardiac sarcomere inhibitors

Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, and Rare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Compounds, compositions and methods

Provided herein is a process for the preparation of (R)—N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.

Process for preparing aficamten

Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R, R, R, G, G, and Gare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Provided herein are compounds of formula (1): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X, X, R, R, R, R, R, and Rare as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Bicyclic 1,4-diazepanones and therapeutic uses thereof

Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein X, R, R, and Rare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Salt of omecamtiv mecarbil and process for preparing salt

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

Bisamide sarcomere activating compounds and uses thereof

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Tetrahydroisoquinoline derivatives

Growing community of inventors

Moraga, CA, United States of America

Bradley Paul Morgan